Stefano Cavalieri
University of Milan
CancerInternal medicineRadiologyOncologyAdverse effectLenvatinibHead and neck cancerChemotherapyHead and neck squamous-cell carcinomaImmunotherapySalivary gland cancerRadiomicsAdenoid cystic carcinomaCetuximabSalivary duct carcinomaMetastatic melanomaHead and neckCancer researchRadiation therapyClinical trialMedicineCohort
74Publications
8H-index
297Citations
Publications 73
Newest
#1Simon Keek (UM: Maastricht University)H-Index: 5
#2Frederik W.R. Wesseling (Maastricht University Medical Centre)H-Index: 5
Last. Ralph T.H. LeijenaarH-Index: 29
view all 0 authors...
Background: Locoregionally advanced head and neck squamous cell carcinoma (HNSCC) patients have high relapse and mortality rates. Imaging-based decision support may improve outcomes by optimising personalised treatment, and support patient risk stratification. We propose a multifactorial prognostic model including radiomics features to improve risk stratification for advanced HNSCC, compared to TNM eighth edition, the gold standard. Patient and methods: Data of 666 retrospective- and 143 prospec...
Source
#1Cristiana Bergamini (University of Milan)H-Index: 20
#2Robert L. Ferris (University of Pittsburgh)H-Index: 92
Last. Lisa Licitra (University of Milan)H-Index: 67
view all 0 authors...
Hemorrhage in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) may be attributed to chemotherapy and local tumor irradiation. Evidence of the relationship between hemorrhage in R/M HNSCC and targeted therapies, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors, or immune checkpoint inhibitors, is limited. We aimed to identify epidemiological and clinical data related to the occurrence of hemorrhage in R/M HNS...
Source
Source
#1Stefano Cavalieri (University of Milan)H-Index: 8
#2Elena Colombo (University of Milan)H-Index: 13
Last. Lisa Licitra (University of Milan)H-Index: 67
view all 15 authors...
OBJECTIVE: To capture and monitor flu-like symptoms in relation to the clinical characteristics and the oncologic treatment of a large head and neck cancer (HNC) patient cohort during the Coronavirus disease 2019 (COVID-19) pandemic. METHODS: Patients were monitored through by 2 rounds of interviews. Clinical characteristics of patients with no symptoms (group 0) and of those reporting ⩾1 (group A), ⩾3 (group B), or ⩾5 symptoms (group C) were analyzed. Patients with ⩾1 symptom at both in...
Source
#1Daria Maria Filippini (UNIBO: University of Bologna)H-Index: 2
#2Milo Gatti (UNIBO: University of Bologna)H-Index: 6
Last. Lisa Licitra (University of Milan)H-Index: 67
view all 9 authors...
Although immune checkpoint inhibitors (ICIs) are associated with different immune-related adverse events (irAEs), the potential effect on the skeleton is poorly defined albeit biologically plausible and assessable through pharmacovigilance. We described a case series of patients experiencing skeletal fractures while on ICIs at the National Cancer Institute of Milan. To better characterize the clinical features of skeletal irAEs reported with ICIs, we queried the FDA Adverse Reporting System (FAE...
Source
#1Stefano Cavalieri (University of Milan)H-Index: 8
#2Lisa Licitra (University of Milan)H-Index: 67
Source
#1Francesca Platini (University of Milan)H-Index: 5
#2Stefano Cavalieri (University of Milan)H-Index: 8
Last. Laura D. Locati (University of Milan)H-Index: 31
view all 12 authors...
PURPOSE Radioactive-iodine (RAI)-resistant differentiated thyroid cancer (DTC) patients benefit from multi-kinase inhibitors (MKIs), such as lenvatinib. Incidence of treatment-related (TR) late toxicities has been not yet described. METHODS From January 2015 to June 2019 we retrospectively reviewed clinical records of patients with RAI-resistant DTC treated with lenvatinib at Istituto Nazionale dei Tumori (Milan, Italy). New side effect of any grade, appeared after 12 months of lenvatinib, was d...
Source
#2Paola OstanoH-Index: 19
Last. Giovanna ChiorinoH-Index: 37
view all 21 authors...
Oropharynx squamous cell carcinoma (OPSCC) is a subtype of head and neck squamous cell carcinoma (HNSCC) arising from the base of the tongue, lingual tonsils, tonsils, oropharynx or pharynx. The majority of HPV-positive OPSCCs has a good prognosis, but a fraction of them has a poor prognosis, similar to HPV-negative OPSCCs. An in-depth understanding of the molecular mechanisms underlying OPSCC is mandatory for the identification of novel prognostic biomarkers and/or novel therapeutic targets. 14...
Source
PURPOSE To describe the management and outcomes of loco-regionally advanced (stages III-IV) laryngeal cancer (LRALC) in elderly patients. METHODS Clinical records of 88 LRALC patients treated at our Institution from 2002 to 2017 were retrospectively reviewed. Patients were divided in 2 subgroups: age > 65 years (elderly) and age ≤ 65 years (controls). Survivals were estimated with Kaplan-Meier method and compared with log-rank test, multivariate analysis were performed with Cox proportional haza...
Source
Background Despite advances in treatments, 30% to 50% of stage III-IV head and neck squamous cell carcinoma (HNSCC) patients relapse within 2 years after treatment. The Big Data to Decide (BD2Decide) project aimed to build a database for prognostic prediction modeling. Methods Stage III-IV HNSCC patients with locoregionally advanced HNSCC treated with curative intent (1537) were included. Whole transcriptomics and radiomics analyses were performed using pretreatment tumor samples and computed to...
Source